Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
Express Scripts
Mallinckrodt
Baxter

Last Updated: August 11, 2022

Investigational Drug Information for Filanesib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Filanesib?

Filanesib is an investigational drug.

There have been 5 clinical trials for Filanesib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Leukemia, Plasma Cell. The leading clinical trial sponsors are Array BioPharma, Pfizer, and PETHEMA Foundation.

There are one hundred and forty-five US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Filanesib
TitleSponsorPhase
Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseAdknoma Health ResearchPhase 2
Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseMerck Sharp & Dohme Corp.Phase 2
Pembrolizumab (MK-3475) in MM Patients With Residual DiseasePETHEMA FoundationPhase 2

See all Filanesib clinical trials

Clinical Trial Summary for Filanesib

Top disease conditions for Filanesib
Top clinical trial sponsors for Filanesib

See all Filanesib clinical trials

US Patents for Filanesib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Filanesib See Plans and Pricing Remote loading of sparingly water-soluble drugs into lipid vesicles ZONEONE PHARMA, INC. (San Francisco, CA) See Plans and Pricing
Filanesib See Plans and Pricing Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) See Plans and Pricing
Filanesib See Plans and Pricing Peptidomimetic macrocycles as modulators of MCL-1 AILERON THERAPEUTICS, INC. (Cambridge, MA) See Plans and Pricing
Filanesib See Plans and Pricing Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Filanesib

Drugname Country Document Number Estimated Expiration Related US Patent
Filanesib Australia AU2015301234 2034-08-04 See Plans and Pricing
Filanesib Canada CA2962709 2034-08-04 See Plans and Pricing
Filanesib China CN106999419 2034-08-04 See Plans and Pricing
Filanesib European Patent Office EP3177269 2034-08-04 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
Express Scripts
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.